Drugs / tumor necrosis factor
tumor necrosis factor
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00436410 | Dec 2006 → Aug 2009 | adrenal cortex carcinoma, breast cancer, colorectal cancer, cutaneous melanoma +4 | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT00002262 | — | HIV infectious disease, Kaposi's sarcoma | University of California, San Francisco | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00019968 | Aug 1999 → Mar 2002 | soft tissue sarcoma | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 2 | NCT00001004 | ? → Feb 1990 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00003789 | Mar 1999 → Jan 2004 | melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00001296 | Feb 1992 → Oct 2000 | melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tumor Necrosis Factor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001004 ↗ |
| Known as | NSC-635257 | “Tumor Necrosis Factor (Knoll), TNF, NSC-635257; Interferon gamma (Genentech), IFN-G, NSC-600662.” NCT00001296 ↗ |
| Known as | Recombinant Tumor Necrosis Factor | “Recombinant Tumor Necrosis Factor and Recombinant Human Interferon-gamma in Patients With AIDS Related Complex” NCT00001004 ↗ |
| Known as | TNF | “To evaluate tolerance, toxicity, and preliminary evidence of antitumor efficacy of intralesionally administered tumor necrosis factor (TNF) and to define a maximum tolerated...” NCT00002262 ↗2“Arm I: Patients receive isolated limb perfusion (ILP) with tumor necrosis factor (TNF) and melphalan.” NCT00019968 ↗ “Tumor Necrosis Factor (Knoll), TNF, NSC-635257; Interferon gamma (Genentech), IFN-G, NSC-600662.” NCT00001296 ↗ |
| Action | Inhibit | “TNF and IFN-G, in combination, can not only inhibit HIV infection of previously uninfected cells” NCT00001004 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant TNF” NCT00001004 ↗ |
| Route | Intramuscular | “TNF alone by intramuscular injection (IM)” NCT00001004 ↗ |